We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Apo E Linked to Epilepsy After Traumatic Brain Injury

By Biotechdaily staff writers
Posted on 03 Jul 2003
A study has found that individuals carrying the gene for the epsilon 4 variation of apolipoprotein E (apo E) were 2.41 times more likely to develop epileptic-type seizures after traumatic brain injury than those not carrying the gene.

About ten years ago, Apo E was linked to increased risk for development of Alzheimer's disease. More...
In the current study, which was published in the June 2003 issue of the Archives of Neurology, investigators examined the linkage between Apo E and the development of epileptic-type seizures after traumatic brain injury.

A group of 106 patients with moderate-to-severe brain injuries were evaluated six months after having been admitted to hospital. In addition, DNA samples were examined to determine the patients' Apo E variant.

Of the 106 patients, 29 had the epsilon 4 variation of apoE, and 77 did not. Of the apoE carriers, 34% had post-traumatic seizures, while only 14% of those without the gene had seizures.

"Post-traumatic epilepsy is a common and frequently disabling complication of traumatic brain injury, for which there is no effective prophylactic therapy,” explained first author Dr. Diaz-Arrastia, associate professor of neurology at the University of Texas Southwestern Medical Center (Dallas, USA; ). "What this finding indicates is that if we learn to manipulate aspects of lipid or lipoprotein metabolism in the brain we may be able to develop therapies to prevent post-traumatic epilepsy.




Related Links:
University of Texas Southwestern Medical Center

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.